GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Capex-to-Operating-Income

ESSA Pharma (ESSA Pharma) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

ESSA Pharma's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-10.49 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


ESSA Pharma Capex-to-Operating-Income Historical Data

The historical data trend for ESSA Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Capex-to-Operating-Income Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ESSA Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ESSA Pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, ESSA Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Capex-to-Operating-Income falls into.



ESSA Pharma Capex-to-Operating-Income Calculation

ESSA Pharma's Capex-to-Operating-Income for the fiscal year that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -32.134
=N/A

ESSA Pharma's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -10.493
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ESSA Pharma  (NAS:EPIX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


ESSA Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

ESSA Pharma (ESSA Pharma) Headlines

From GuruFocus

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

By PRNewswire PRNewswire 06-06-2023